The Company headquarters is in Valencia, Spain.įor more information, please visit and engage with us on LinkedIn. ARTHEx is also advancing its in-house discovery engine to identify and develop microRNA modulators for other disorders with high unmet medical needs, including genetically-driven diseases like DM1. Type of disorder: Clinical Significance: Detects CTG repeat expansions in the muscle protein kinase (DMPK) gene Specimen. The Company's lead investigational compound, ATX-01, is advancing into clinical development for the treatment of myotonic dystrophy type 1 (DM1), a rare progressive muscle wasting disease. In December 2022, ARTHEx announced the achievement of key regulatory milestones for the ATX-01 development program, including receiving Orphan Drug Designation for ATX-01 in DM1 from both the US and European authorities.ĪTX-01 was discovered through ARTHEx' in-house discovery engine, which is designed to identify and optimize novel microRNA modulators and ensure their preferential delivery to targeted tissues, for the treatment of diseases in which microRNAs are involved in the disease pathogenesis.ĪRTHEx Biotech is a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs. Toxic DMPK and reduced levels of MBNL have been identified as the genetic cause of DM1. It has been demonstrated in human DM1 myoblast cell lines that ATX-01 has a unique, dual mechanism of action which targets toxic DMPK and MBNL proteins. Beatriz Llamusi, Chief Scientific Officer & Co-Founder of ARTHEx Location: Manchester Grand Hyatt, San Diego, CAĪTX-01 is an antimiR designed to target microRNA 23b (miR-23b), which is associated with regulating the expression of MBNL protein involved in the pathogenesis of DM1. Title: "Preclinical Development of a Lipophilic-conjugated Antimir to Treat Myotonic Dystrophy Type 1 (DM1)" Date: Wednesday, Time: 8:30 am PT Presenter: Dr. Instructions on how to implement this are listed in the notes section of the configuration tab.VALENCIA, Spain, /PRNewswire/ - ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, announced today a presentation at the TIDES USA Oligonucleotide & Peptide Therapeutics annual meeting being held May 7-10, 2023, in San Diego, CA. Since these pages are on the popup layer, buttons not in use must be disabled to prevent lower layer buttons from functioning. There are two page views, one shows the pop-up messages and the other displays just a lamp status icon that allows the user to recall the message page view. Patients with larger repeats tend to have a more severe phenotype. Custom code handles displaying the information in a pop-up page view based on system variables and events as well as navigating through the list of codes. Myotonic dystrophy type 1 (DM1) is caused by expansion of a CTG triplet repeat in the 3 untranslated region of the DMPK gene that encodes a serine-threonine kinase. As codes expire they are automatically removed from the list. The Diagnostic app handles receiving the data, populating the DM1 List, and setting the current lamp status, events and variables. ![]() ![]() This can also be used for internally generated faults by using the Internal DM1 functions. This version will work on any of the color display platforms.ĭM1 messages are currently active codes and will be transmitted by the ECU when there are one or more active faults. This example provides full DM1 pop-up messaging with lamp status.
0 Comments
Leave a Reply. |